293 PREDICTORS OF RELAPSE AMONG PATIENTS TREATED WITH STANDARD OR INDUCTION DOSE PEGINTERFERON ALFA-2A (40KD) COMBINED WITH STANDARD OR HIGHER DOSE RIBAVIRIN IN DIFFICULT-TO-CURE PATIENTS

293 PREDICTORS OF RELAPSE AMONG PATIENTS TREATED WITH STANDARD OR INDUCTION DOSE PEGINTERFERON ALFA-2A (40KD) COMBINED WITH STANDARD OR HIGHER DOSE RIBAVIRIN IN DIFFICULT-TO-CURE PATIENTS K.R. Reddy, M.L. Shiffman, M. Rodriguez-Torres, I. Bakulin, H. Cheinquer, A. Horban, M. El-Kashab, L. Gheohge, P. Buggisch, M. Rabbia, M. McKenna, S.A. Harrison, On behalf of the PROGRESS Study Investigators. Hospital of the University of Pennsylvania, Philadelphia, PA, Bon Secours Health System, Liver Institute of Virginia, Newport News, VA, Fundacion de Investigacion de Diego Santurce, Puerto Rico and Ponce School of Medicine, Santurce, PR, USA; State Postgraduate Medical Institute, Ministry of Defence of the Russian Federation, Moscow, Russia; Hospital de Clinicas de Porto Alegre, Porte Alegre, Brazil; Medical University Clinic of Infectious Diseases, Warsaw, Poland; Toronto Liver Centre, Toronto, ON, Canada; Fundeni Clinical Institute, Bucharest, Romania; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Roche, Nutley, NJ, USA; Roche, Welwyn, UK; Brooke Army Medical Center, Houston, TX, USA E-mail: rajender.reddy@uphs.upenn.edu